During his State of the University address, President Jim Davis highlighted plans to use AI in healthcare and announced the ...
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") will present new exploratory analyses from the global Phase 3 SCORPIO-PEP study, ...
Ascentage Pharma receives China's Breakthrough Therapy Designation for lisaftoclax plus acalabrutinib in untreated CLL/SLL as ...
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical ...
Shanghai, China - October 16, 2026 - MicroPort Scientific Corporation announced that it and its associated companies have reached a cumulative total of 50 products accepted into China's National ...
Envoy has submitted 2 of 4 planned FDA modules and expects to submit its final trial-data module by end-Q2 2027; 12-month ...
The 13-point charter also called for the restoration of GSCASH, the return of JNUEE and action on wider concerns over campus ...
Approval based on phase III data showing unprecedented functional cure rates compared to standard of care ...
The presentation will provide congress attendees, clinical investigators, members of the neuro-ophthalmology and multiple sclerosis communities with an opportunity to hear directly from Professor ...
Ascentage Pharma Group International announced that lisaftoclax (APG-2575), the Company's novel Bcl-2 inhibitor, has been granted a Breakthrough Therapy Designation (BTD) by the Center for Drug ...
We break down the first FDA-approved myopia treatment glasses, candidate eligibility for kids, and daily wear expectations.
Why is Orange County the medical device capital? Explore the founders, M&A trends, and regulatory strategies driving OC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results